CY1109981T1 - Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης - Google Patents

Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης

Info

Publication number
CY1109981T1
CY1109981T1 CY20101100368T CY101100368T CY1109981T1 CY 1109981 T1 CY1109981 T1 CY 1109981T1 CY 20101100368 T CY20101100368 T CY 20101100368T CY 101100368 T CY101100368 T CY 101100368T CY 1109981 T1 CY1109981 T1 CY 1109981T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
gastric injury
gaba
gaba analysis
Prior art date
Application number
CY20101100368T
Other languages
English (en)
Inventor
Antonio Guglietta
Charles Price Taylor Jr
Jiayuan Ren
W P Watson
Michael Francis Rafferty
Laurent Diop
Maria Chovet
Lionel Bueno
Hilary J Little
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of CY1109981T1 publication Critical patent/CY1109981T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Ανάλογα του GABA είναι χρήσιμα για την πρόληψη και αγωγή γαστρεντερικής βλάβης και συνδρόμου αποστέρησης αιθανόλης. Οι προτιμώμενες αγωγές κάνουν χρήση της γαβαπεντίνης ή της πρεγαβαλίνης.
CY20101100368T 1997-08-20 2010-04-26 Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης CY1109981T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US7479498P 1998-02-16 1998-02-16
US8293698P 1998-04-24 1998-04-24
EP98945758A EP1009399B1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Publications (1)

Publication Number Publication Date
CY1109981T1 true CY1109981T1 (el) 2014-09-10

Family

ID=27369092

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100368T CY1109981T1 (el) 1997-08-20 2010-04-26 Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης

Country Status (25)

Country Link
US (2) US6242488B1 (el)
EP (1) EP1009399B1 (el)
JP (1) JP4681116B2 (el)
KR (2) KR100609359B1 (el)
AT (1) ATE461698T1 (el)
AU (2) AU8668598A (el)
BR (1) BR9812133A (el)
CA (1) CA2297163C (el)
CO (1) CO4960645A1 (el)
CY (1) CY1109981T1 (el)
DE (1) DE69841574D1 (el)
DK (1) DK1009399T3 (el)
ES (1) ES2341154T3 (el)
HU (1) HUP0004551A3 (el)
IL (1) IL134164A (el)
IS (1) IS2749B (el)
MY (1) MY155223A (el)
NO (1) NO327983B1 (el)
NZ (1) NZ502729A (el)
PE (1) PE107299A1 (el)
PL (1) PL194125B1 (el)
PT (1) PT1009399E (el)
TW (2) TW570794B (el)
UY (1) UY25148A1 (el)
WO (2) WO1999008670A1 (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
DE69832712T2 (de) 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
AU3216600A (en) 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
ES2287021T3 (es) 1999-07-22 2007-12-16 University Of Rochester Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje.
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
AU2001259627A1 (en) 2000-05-16 2001-11-26 Warner Lambert Company Cell line for the expression of an alpha2delta2 calcium channel subunit
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011565A (es) 2001-06-11 2004-10-28 Xenoport Inc Profarmacos de analogos de gaba, composiciones y usos de las mismas.
ES2253579T3 (es) * 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
CA2476438A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
BR0312568A (pt) * 2002-07-10 2005-05-03 Warner Lambert Co Composições gastrointestinais compreendendo derivados de gaba
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
WO2004054560A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2508297A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CA2518218A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc Tetrazole and oxadiazolone substituted .beta.-amino acid derivatives
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
JP4308263B2 (ja) 2003-10-14 2009-08-05 ゼノポート，インコーポレイティド γ−アミノ酪酸アナログの結晶形
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
DE602005002253T2 (de) * 2004-03-12 2008-05-29 Warner-Lambert Company Llc C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
JP2007530657A (ja) * 2004-04-01 2007-11-01 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐキラル性ホスホランの調製および不斉合成でのその使用
MXPA06014228A (es) * 2004-06-21 2007-02-14 Warner Lambert Co Preparacion de pregabalina y compuestos relacionados.
ES2347581T3 (es) * 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
JP2008518971A (ja) 2004-11-04 2008-06-05 ゼノポート，インコーポレイティド ガバペンチンプロドラッグ持続放出経口薬剤
JP5271087B2 (ja) 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP2010512314A (ja) * 2006-12-08 2010-04-22 ゼノポート，インコーポレーテッド 疾患を治療するためのｇａｂａアナログのプロドラッグの使用
WO2009055059A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US8062870B2 (en) 2008-01-25 2011-11-22 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CN102216257B (zh) 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法
MX347467B (es) * 2009-06-22 2017-04-26 Wyeth Llc Comprimidos de ibuprofeno de sodio y procedimientos de fabricación de composiciones farmacéuticas que incluyen ibuprofeno de sodio.
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2948139B1 (en) 2013-01-28 2019-06-12 Lopez, Hector, L. Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
WO2017177160A1 (en) * 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
CA3075414A1 (en) 2017-10-03 2019-04-11 Nevakar Inc. Acetaminophen-pregabalin combinations and methods of treating pain
JP7441181B2 (ja) 2018-05-14 2024-02-29 エックスジーン ファーマシューティカル インク． ナプロキセンとプレガバリンの１－（アシルオキシ）－アルキルカルバメート薬品複合体の結晶形態

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (el)
DE1963925C3 (de) 1969-12-20 1975-07-10 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
AU2929489A (en) 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
SG48288A1 (en) * 1992-05-20 1998-04-17 Univ Northwestern Gaba and l-glutamic acid analogs for antiseizure treatment
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
PL319029A1 (en) 1994-09-02 1997-07-21 Univ Virginia Commonwealth Pain relieving preparation containing non-nercotic analgesic compound and analgesic action enhancing compound
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
EP0937032B1 (en) * 1996-10-23 2007-05-09 Warner-Lambert Company LLC Substituted gamma aminobutyric acids as pharmaceutical agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
PL338705A1 (en) 2000-11-20
CA2297163A1 (en) 1999-02-25
PL194125B1 (pl) 2007-04-30
NO20000786D0 (no) 2000-02-17
TWI251485B (en) 2006-03-21
HUP0004551A2 (hu) 2001-05-28
UY25148A1 (es) 1999-01-26
HUP0004551A3 (en) 2002-11-28
US6426368B2 (en) 2002-07-30
PT1009399E (pt) 2010-05-21
BR9812133A (pt) 2000-07-18
TW200412938A (en) 2004-08-01
DK1009399T3 (da) 2010-05-31
US20010014698A1 (en) 2001-08-16
ES2341154T3 (es) 2010-06-15
WO1999008671A1 (en) 1999-02-25
KR20050116168A (ko) 2005-12-09
KR20010023084A (ko) 2001-03-26
WO1999008670A1 (en) 1999-02-25
ATE461698T1 (de) 2010-04-15
KR100609359B1 (ko) 2006-08-04
PE107299A1 (es) 1999-12-19
EP1009399B1 (en) 2010-03-24
NO327983B1 (no) 2009-11-02
NZ502729A (en) 2002-10-25
JP4681116B2 (ja) 2011-05-11
IL134164A (en) 2005-05-17
AU8668598A (en) 1999-03-08
MY155223A (en) 2015-09-30
US6242488B1 (en) 2001-06-05
AU9293098A (en) 1999-03-08
IS2749B (is) 2011-08-15
EP1009399A1 (en) 2000-06-21
IS5361A (is) 2000-01-25
JP2001515033A (ja) 2001-09-18
CA2297163C (en) 2001-11-20
IL134164A0 (en) 2001-04-30
CO4960645A1 (es) 2000-09-25
DE69841574D1 (de) 2010-05-06
NO20000786L (no) 2000-02-17
TW570794B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
CY1109981T1 (el) Αναλογα του gaba για την προληψη και αγωγη γαστρεντερικης βλαβης
BR9603841A (pt) Aparelho para o tratamento hipertérmico de tumores
DK0835637T3 (da) Behandlingstilbehør til endeskop
DK0834278T3 (da) Behandlingstilbehør til endoskop
DK5098A (da) Endoskopisk behandlingsinstrument
DE69623722D1 (de) Blutbehandlungsgerät
DE69825447D1 (de) Gerät zur dermatologischen behandlung
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
PT705100E (pt) Guanidinas substituidas terapeuticas
CY1107116T1 (el) Νεες κυκλοεξυλ σουλφονες
IT1308739B1 (it) Dispositivo di trattamento di un nastro allungato
ITTO950529A0 (it) Dispositivo e procedimento per la realizzazione di catene di ortidoti lunghezza ridotta
ES1037776Y (es) Dispositivo para el tratamiento de los pies.
IT8820299A0 (it) Composti utili per il trattamento e diagnosi di disfunzioni erettili.
HUP0000523A2 (hu) Éterlipid/kiegészítő alakú lipid kombinációt tartalmazó hordozók és terápiai alkalmazásuk
DE69412806D1 (de) Gerät für medizinische behandlungen
IT1305926B1 (it) Dispositivo di trazione per la lavorazione di catene ornamentali
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
KR950018715U (ko) 오 · 폐수 처리용 산기 장치
FR2700270B1 (fr) Appareil portable d'echauffement et de forcage de la cambrure du pied.
ES1035980Y (es) Dispositivo para el tratamiento de liquidos.
ES1030216Y (es) Cinturon terapeutico para el tratamiento de la impotencia.
DK0734514T3 (da) Vævsprøvebehandling
CY1105220T1 (el) Χρηση αναστολεων nf-κβ για την αγωγη των διαταραχων ξηροφθαλμιας
ES1024499Y (es) Aparato portatil para hidromasaje.